Takeda grabs Ariad, expands oncology portfolio in $5.2B buyout
Takeda has taken the next step in its global restructuring, bagging Ariad Pharmaceuticals for $5.2 billion and paying a whopping 74% premium for its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.